Baseline Factors as Predictors of Clinical Progression of Benign Prostatic Hyperplasia in Men Treated With Placebo

Crawford, E. David; Wilson, Shandra; McConnell, John D.; Slawin, Kevin M.; Lieber, Michael; Smith, Joseph A.; Meehan, Alan G.; Bautista, Oliver; Noble, William R.; Kusek, John W.; Nyberg, Leroy M.; Roehrborn, Claus G.

doi:10.1016/s0022-5347(05)00708-1

Cited by 207 publications

(155 citation statements)

References 17 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…Baseline total prostate volume, PSA, Qmax, post void residue and age were important predictors of the risk of clinical progression of BPH (Crawford et al, 2006). According to our results, NLR, with a cut-off value of 1.99, can be used in conjunction with other parameters in predicting the progression of BPH.…”

Section: Discussionmentioning

confidence: 51%

“…The low risk group was characterized by a PSA <1.6ng/mL, prostate volume <31mL, age <62 years, IPPS <20 points, Qmax ≥10.6mL/second; the high risk group included individuals with a PSA ≥1.6 ng/ mL, prostate volume ≥31mL, age ≥62 years, IPPS ≥20 points, and Qmax <10.6mL/second (Crawford et al, 2006;SpringerBasicRoehrborn et al, 2014). NLR was compared between the low-and high-risk groups.…”

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Is the Neutrophil-Lymphocyte Ratio an Indicator of Progression in Patients with Benign Prostatic Hyperplasia?

Tanık

Albayrak²,

Zengın³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: The aim of this study was to evaluate inflammation parameters and assess the utility of the neutrophillymphocyte ratio (NLR) as a simple and readily available predictor for clinical disease activity in patients with nenign prostate hyperplasia BPH. We also aimed to investigate the relationship between inflammatory parameters with α-blocker therapy response, and evaluate the potential association between NLR and the progression of benign prostatic hyperplasia (BPH). Materials and Methods: We examined 320 consecutive patients ( .001); however, there were no significant differences between the groups in terms of age (p>0.05), and prostate volume (p>0.05). Conclusions: NLR can predict BPH progression. We propose that increased inflammation is negatively associated with clinical status in BPH patients and suggest that NLR can give information along with LUTS severity which may be used as a readikly accessible marker for patient follow-up.

show abstract

Section: Discussionmentioning

confidence: 51%

Section: Study Populationmentioning

confidence: 99%

Is the Neutrophil-Lymphocyte Ratio an Indicator of Progression in Patients with Benign Prostatic Hyperplasia?

Tanık

Albayrak²,

Zengın³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In medical therapy of prostate symptoms, subjects in the placebo arm with a baseline PVR greater than 39 ml had statistically significant higher progression rates, including symptom score progression, rates of AUR and surgical therapy. 72 In patients on medical therapy, however, baseline PVR did not predict outcomes. 79 Overall, in clinical trials, the importance of PVR as a predictor of BPH progression may be underestimated, as most trials exclude patients with large baseline PVRs.…”

Section: Post-void Residual Volumementioning

confidence: 99%

“…71 In the placebo arm of the medical therapy of prostate symptoms, men with a maximum flow rate o10.6 ml s À1 at baseline had a greater risk of overall progression, symptomatic progression and incidence of surgical intervention. 72 Maximum flow rates have been seen to exhibit an age-related component. The decrease in urinary flow rates with age is approximately linear.…”

Section: Maximum Flow Ratesmentioning

confidence: 99%

Voiding dysfunction in men: pathophysiology and risk factors

Scofield

Kaplan

2008

Int J Impot Res

View full text Add to dashboard Cite

“…1,2 Crawford et al reported that a PV of ≥31 mL was one of the important predictors for the risk of clinical progression of BPH, including progression of the International Prostate Symptoms Score, the occurrence of urinary retention and development to an invasive procedure. 3 For the BPH patient who has an enlarged prostate with a size >30 mL, previous large clinical trials such as the MTOPS trial and CombAT trial showed the effectiveness of combination therapy with a 5-a-reductase inhibitor and an ablocker. 4,5 Although the risks and treatment for the enlarged prostate have been reported, there have not been many reports on evaluation of the PV.…”

Section: Introductionmentioning

confidence: 99%

Does digital rectal examination predict prostate volume greater than 30 mL?

2017

View full text Add to dashboard Cite

Abbreviations & Acronyms BPH = benign prostatic hyperplasia DRE = digital rectal examination F = flat LUTS = lower urinary tract symptoms LUTS/BPH = lower urinary tract symptoms suggestive of benign prostatic hyperplasia Ma = markedly enlarged Mo = moderately enlarged N = normal PV = prostate volume S = slightly enlarged TRUS = transrectal ultrasound Objectives: To investigate the accuracy of digital rectal examination in estimating prostate volume in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Methods: A community-based study was carried out in Japan to investigate the prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. A total of 457 men were screened and deemed eligible for the present analysis. Findings on digital rectal examination were compared with prostate volume measurement by transrectal ultrasound. Five groups were identified on digital rectal examination: flat, normal, slightly enlarged, moderately enlarged and markedly enlarged. Results: The median age and prostate volume were 64 years and 19.7 mL, respectively. Prostate volumes for the flat, normal, slightly enlarged, moderately enlarged, and markedly enlarged groups were 16.4, 18.3, 27.0, 41.9 and 86.3 mL, respectively. There were significant differences in prostate volume between the groups. The positive predictive value was 94.1% if flat, and normal were assumed to have a prostate volume <30 mL. The value was 80.8% if moderately enlarged, and markedly enlarged were assumed to have a prostate volume ≥30 mL. Of the men in the slightly enlarged group, 61.0% had a prostate volume <30 mL. Conclusions: It is possible to stratify prostate volume according to digital rectal examination. We could determine the prostates in the flat and normal groups to have a prostate volume <30 mL, and those in the moderately enlarged and markedly enlarged groups to have a prostate volume ≥30 mL by digital rectal examination with high accuracy. Transrectal ultrasound was required for those in the slightly enlarged group.

show abstract

Baseline Factors as Predictors of Clinical Progression of Benign Prostatic Hyperplasia in Men Treated With Placebo

Abstract: Among men in the placebo arm, baseline TPV, PSA, Qmax, PVR and age were important predictors of the risk of clinical progression of BPH.

Cited by 207 publications

References 17 publications

Is the Neutrophil-Lymphocyte Ratio an Indicator of Progression in Patients with Benign Prostatic Hyperplasia?

Is the Neutrophil-Lymphocyte Ratio an Indicator of Progression in Patients with Benign Prostatic Hyperplasia?

Voiding dysfunction in men: pathophysiology and risk factors

Does digital rectal examination predict prostate volume greater than 30 mL?

Contact Info

Product

Resources

About